Loading market dashboard
Ajinomoto Co., Inc.
AJINYConsumer DefensiveOTCJP
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
I am initiating on Ajinomoto with a 'Hold' rating, after evaluating its results and outlook. The company's FY2025 EPS beat the consensus forecast, but its FY26 business profit guidance implies a substantial growth deceleration. There is also a significant divergence in the prospects of its Ajinomoto Build-up Film/ABF and frozen foods businesses.
J. M. Smucker (NYSE: SJM - Get Free Report) and Ajinomoto (OTCMKTS:AJINY - Get Free Report) are both large-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings. Valuation and Earnings This table compares
Piramal Pharma Solutions is a global leader in antibody-drug conjugate (ADC) development and manufacturing, leveraging over 20 years of specialized experience to support partners from early-stage to commercialization. Ajinomoto Bio-Pharma Services is a leading provider of biopharmaceutical manufacturing services and platform technologies, responsible for the development of AJICAP™, a set of proprietary technologies designed to facilitate the creation of site-specific ADCs and linkers.
An activist investor has built a stake in a Japanese company it says has a lucrative monopoly on a material vital to artificial-intelligence infrastructure.
J. M. Smucker (NYSE: SJM - Get Free Report) and Ajinomoto (OTCMKTS:AJINY - Get Free Report) are both large-cap consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends. Analyst Ratings This is a summary
LONDON--(BUSINESS WIRE)--Palliser Capital (“Palliser”), a top 25 shareholder of Ajinomoto Co., Inc. (“Ajinomoto” or the “Company”), today published a comprehensive presentation outlining the opportunities available to unlock significant long‑term value at Ajinomoto. To promote market transparency and respond to growing interest from shareholders and other stakeholders, Palliser has made public a detailed presentation titled “Maximising the Value of Ajinomoto – The Most Under‑Monetised AI Infras.
